XCSport体育

<form id='7wtz8'></form>

<bdo id='7wtz8'><sup id='7wtz8'><div id='7wtz8'><bdo id='7wtz8'></bdo></div></sup></bdo>

Be the most trusted biotech company

2025-10-30

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
2025-10-24

First Patient in Japan Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2025-10-23

HLX22 Dual HER2 Blockade Therapy Featured on the Cover of Med
2025-10-21

Henlius Receives Approval in Japan for Phase 3 MRCT of Dual HER2 Blockade Therapy on First-Line HER2+ GC
2025-10-14

Henlius Shines at CPHI Worldwide 2024, Expanding New Opportunities for International Collaboration
2025-09-30

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
2025-09-21

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
2025-09-18

Latest Results of HANSIZHUANG and HANQUYOU Released at 2024 ESMO
2025-09-13

Meet Henlius at CPHI Worldwide 2024